Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 24 investigational indications.
targets Aromatic-L-amino-acid decarboxylase
all catalysts(0) nothing on the calendar yet
News(0) no news has mentioned this drug yet
trade names
Carbidopa, Carbidopa component of corbilta, Carbidopa component of crexont, Carbidopa component of dhivy, Carbidopa component of dopasnap, Carbidopa component of duopa
MOA
12.1 Mechanism of Action Carbidopa When levodopa is administered orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain. Levodopa Levodopa is the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa treats the symptoms of Parkinson's disease.
indication
1 INDICATIONS AND USAGE DUOPA ® is indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease. DUOPA is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease ( 1 )
comments(0)
5-min edit window · permanent after that